Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized study of cisplatin (NSC 119875) and Taxol (paclitaxel) (NSC 125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma

Next Previous
X
Search
Trial Profile

A phase III randomized study of cisplatin (NSC 119875) and Taxol (paclitaxel) (NSC 125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 May 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
    • 12 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top